For research use only. Not for therapeutic Use.
Fosdagrocorat(CAT: I006604) is a prodrug of Dagrocorat, a selective glucocorticoid receptor modulator (SGRM), designed to reduce inflammation while minimizing the side effects commonly associated with traditional glucocorticoids. Upon administration, Fosdagrocorat is converted into its active form, Dagrocorat, which selectively modulates glucocorticoid receptors, providing anti-inflammatory effects without significantly impacting metabolic, bone, or immune functions. This compound is of particular interest in the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease. Its targeted action makes it a promising candidate for research into safer, more effective glucocorticoid-based therapies.
Catalog Number | I006604 |
CAS Number | 1044535-58-1 |
Synonyms | PF-04171327; PF04171327; PF 04171327; PF-4171327; PF4171327; PF 4171327; Fosdagrocorat.;(2R,4aS,10aR)-4a-benzyl-7-((2-methylpyridin-3-yl)carbamoyl)-2-(trifluoromethyl)-1,2,3,4,4a,9,10,10a-octahydrophenanthren-2-yl dihydrogen phosphate |
Molecular Formula | C29H30F3N2O5P |
Purity | ≥95% |
Solubility | Soluble in DMSO, not in water |
Storage | Store at -20°C |
IUPAC Name | [(2R,4aS,10aR)-4a-benzyl-7-[(2-methylpyridin-3-yl)carbamoyl]-2-(trifluoromethyl)-1,3,4,9,10,10a-hexahydrophenanthren-2-yl] dihydrogen phosphate |
InChI | InChI=1S/C29H30F3N2O5P/c1-19-25(8-5-15-33-19)34-26(35)22-10-12-24-21(16-22)9-11-23-18-28(29(30,31)32,39-40(36,37)38)14-13-27(23,24)17-20-6-3-2-4-7-20/h2-8,10,12,15-16,23H,9,11,13-14,17-18H2,1H3,(H,34,35)(H2,36,37,38)/t23-,27+,28-/m1/s1 |
InChIKey | BVXLAHSJXXSWFF-KEKPKEOLSA-N |
SMILES | CC1=C(C=CC=N1)NC(=O)C2=CC3=C(C=C2)C4(CCC(CC4CC3)(C(F)(F)F)OP(=O)(O)O)CC5=CC=CC=C5 |